Brian Druker

Professor

  • 67169 Citations
  • 111 h-Index
1981 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

Filter
Review article
2020

Response and Resistance to BCR-ABL1-Targeted Therapies

Braun, T. P., Eide, C. A. & Druker, B. J., Apr 13 2020, In : Cancer Cell. 37, 4, p. 530-542 13 p.

Research output: Contribution to journalReview article

2 Scopus citations
2019

Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia

on behalf of the International CML Foundation Genomics Alliance, Jan 1 2019, In : Leukemia.

Research output: Contribution to journalReview article

14 Scopus citations

Revisiting NTRKs as an emerging oncogene in hematological malignancies

Joshi, S. K., Davare, M. A., Druker, B. J. & Tognon, C. E., Nov 1 2019, In : Leukemia. 33, 11, p. 2563-2574 12 p.

Research output: Contribution to journalReview article

Open Access
3 Scopus citations
2018

Chronic myelogenous leukemia: Pregnancy in the era of stopping tyrosine kinase inhibitor therapy

Berman, E., Druker, B. J. & Burwick, R., Apr 20 2018, In : Journal of Clinical Oncology. 36, 12, p. 1250-1256 7 p.

Research output: Contribution to journalReview article

13 Scopus citations
2015

Cardio-oncology: How new targeted cancer therapies and precision medicine can inform cardiovascular discovery

Bellinger, A. M., Arteaga, C. L., Force, T., Humphreys, B. D., Demetri, G. D., Druker, B. J. & Moslehi, J. J., Dec 8 2015, In : Circulation. 132, 23, p. 2248-2258 11 p.

Research output: Contribution to journalReview article

57 Scopus citations
2007

Applying the discovery of the Philadelphia chromosome

Sherbenou, D. W. & Druker, B. J., Aug 1 2007, In : Journal of Clinical Investigation. 117, 8, p. 2067-2074 8 p.

Research output: Contribution to journalReview article

94 Scopus citations
2006

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

Hughes, T., Deininger, M., Hochhaus, A., Branford, S., Radich, J., Kaeda, J., Baccarani, M., Cortes, J., Cross, N. C. P., Druker, B. J., Gabert, J., Grimwade, D., Hehlmann, R., Kamel-Reid, S., Lipton, J. H., Longtine, J., Martinelli, G., Saglio, G., Soverini, S., Stock, W. & 1 others, Goldman, J. M., Jul 1 2006, In : Blood. 108, 1, p. 28-37 10 p.

Research output: Contribution to journalReview article

909 Scopus citations

Targeted CML therapy: Controlling drug resistance, seeking cure

O'Hare, T., Corbin, A. S. & Druker, B. J., Feb 1 2006, In : Current Opinion in Genetics and Development. 16, 1, p. 92-99 8 p.

Research output: Contribution to journalReview article

152 Scopus citations
2005

Perspective: A program to improve protein biomarker discovery for cancer

Aebersold, R., Anderson, L., Caprioli, R., Druker, B., Hartwell, L. & Smith, R., Jul 1 2005, In : Journal of Proteome Research. 4, 4, p. 1104-1109 6 p.

Research output: Contribution to journalReview article

120 Scopus citations

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

Deininger, M., Buchdunger, E. & Druker, B. J., Apr 1 2005, In : Blood. 105, 7, p. 2640-2653 14 p.

Research output: Contribution to journalReview article

987 Scopus citations
2004

Imatinib: Paradigm or anomaly?

Druker, B. J., Jul 2004, In : Cell Cycle. 3, 7, p. 831-833 3 p.

Research output: Contribution to journalReview article

Open Access
17 Scopus citations

SRCircumventing imatinib resistance

Deininger, M. W. N. & Druker, B. J., Aug 2004, In : Cancer Cell. 6, 2, p. 108-110 3 p.

Research output: Contribution to journalReview article

33 Scopus citations
2003

Imatinib alone and in combination for chronic myeloid leukemia

Druker, B. J., Jan 2003, In : Seminars in Hematology. 40, 1, p. 50-58 9 p.

Research output: Contribution to journalReview article

96 Scopus citations

Imatinib mesylate in the treatment of chronic myeloid leukaemia

Druker, B. J., Jun 1 2003, In : Expert Opinion on Pharmacotherapy. 4, 6, p. 963-971 9 p.

Research output: Contribution to journalReview article

44 Scopus citations

Philadelphia Chromosome-Positive Leukemias: From Basic Mechanisms to Molecular Therapeutics

Kurzrock, R., Kantarjian, H. M., Druker, B. J. & Talpaz, M., May 20 2003, In : Annals of internal medicine. 138, 10, p. 819-830 12 p.

Research output: Contribution to journalReview article

247 Scopus citations

Practical management of patients with chronic myeloid leukemia receiving imatinib

Deininger, M. W. N., O'Brien, S. G., Ford, J. M. & Druker, B. J., Apr 15 2003, In : Journal of Clinical Oncology. 21, 8, p. 1637-1647 11 p.

Research output: Contribution to journalReview article

291 Scopus citations

Specific targeted therapy of chronic myelogenous leukemia with imatinib

Deininger, M. W. N. & Druker, B. J., Sep 2003, In : Pharmacological Reviews. 55, 3, p. 401-423 23 p.

Research output: Contribution to journalReview article

253 Scopus citations

STI571 as a targeted therapy for CML

O'Dwyer, M. E., Mauro, M. J. & Druker, B. J., Sep 10 2003, In : Cancer Investigation. 21, 3, p. 429-438 10 p.

Research output: Contribution to journalReview article

52 Scopus citations
2002

Chronic myelogenous leukemia.

Druker, B. J., O'Brien, S. G., Cortes, J. & Radich, J., 2002, In : Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. p. 111-135 25 p.

Research output: Contribution to journalReview article

Open Access
80 Scopus citations
30 Scopus citations
548 Scopus citations

Perspectives on the development of a molecularly targeted agent

Druker, B. J., Feb 2002, In : Cancer Cell. 1, 1, p. 31-36 6 p.

Research output: Contribution to journalReview article

232 Scopus citations

Recent advancements in the treatment of chronic myelogenous leukemia

O'Dwyer, M. E., Mauro, M. J. & Druker, B. J., Mar 9 2002, In : Annual review of medicine. 53, p. 369-381 13 p.

Research output: Contribution to journalReview article

57 Scopus citations

Recent advances in Philadelphia chromosome-positive malignancies: the potential role of arsenic trioxide.

O'Dwyer, M. E., La Rosée, P., Nimmanapalli, R., Bhalla, K. N. & Druker, B. J., Apr 2002, In : Seminars in hematology. 39, 2 Suppl 1, p. 18-21 4 p.

Research output: Contribution to journalReview article

26 Scopus citations

STI571 (Gleevec™) as a paradigm for cancer therapy

Druker, B. J., Jan 1 2002, In : Trends in Molecular Medicine. 8, 4 SUPPL., p. S14-S18

Research output: Contribution to journalReview article

244 Scopus citations
2001

Bcr-Abl inhibition as a modality of CML therapeutics

Buchdunger, E., Matter, A. & Druker, B. J., Aug 31 2001, In : Biochimica et Biophysica Acta - Reviews on Cancer. 1551, 1, p. M11-M18

Research output: Contribution to journalReview article

91 Scopus citations

Chronic myelogenous leukaemia - New therapeutic principles

O'Dwyer, M. E. & Druker, B. J., Dec 1 2001, In : Journal of Internal Medicine. 250, 1, p. 3-9 7 p.

Research output: Contribution to journalReview article

45 Scopus citations

Chronic myelogenous leukemia

Mauro, M. J. & Druker, B. J., Jan 30 2001, In : Current Opinion in Oncology. 13, 1, p. 3-7 5 p.

Research output: Contribution to journalReview article

75 Scopus citations

Chronic myelogenous leukemia.

Druker, B. J., Sawyers, C. L., Capdeville, R., Ford, J. M., Baccarani, M. & Goldman, J. M., 2001, In : Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. p. 87-112 26 p.

Research output: Contribution to journalReview article

Open Access
97 Scopus citations

Chronic myeloid leukemia: Current treatment options

Goldman, J. M. & Druker, B. J., Oct 1 2001, In : Blood. 98, 7, p. 2039-2042 4 p.

Research output: Contribution to journalReview article

199 Scopus citations

Current treatment approaches for chronic myelogenous leukemia.

Druker, B. J., Jan 1 2001, In : Cancer journal (Sudbury, Mass.). 7 Suppl 1, p. S14-18

Research output: Contribution to journalReview article

21 Scopus citations

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lympoblastic leukemia with the philadelphia chromosome

Zubay, G., Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S. & Sawyers, C. L., Dec 1 2001, In : Chemtracts. 14, 13, p. 733-738 6 p.

Research output: Contribution to journalReview article

Signal transduction inhibition: Results from phase I clinical trials in chronic myeloid leukemia

Druker, B., Jan 1 2001, In : Seminars in Hematology. 38, 3 SUPPL. 8, p. 9-14 6 p.

Research output: Contribution to journalReview article

38 Scopus citations

STI571: a gene product-targeted therapy for leukemia.

Mauro, M. J. & Druker, B. J., May 2001, In : Current oncology reports. 3, 3, p. 223-227 5 p.

Research output: Contribution to journalReview article

32 Scopus citations
2000

Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia

Druker, B. J. & Lydon, N. B., Jan 2000, In : Journal of Clinical Investigation. 105, 1, p. 3-7 5 p.

Research output: Contribution to journalReview article

Open Access
770 Scopus citations

Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemia

O'Dwyer, M. E. & Druker, B. J., Dec 1 2000, In : Current Opinion in Oncology. 12, 6, p. 594-597 4 p.

Research output: Contribution to journalReview article

29 Scopus citations

STI571: An inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia

O'Dwyer, M. E. & Druker, B. J., Jan 1 2000, In : Lancet Oncology. 1, 4, p. 207-211 5 p.

Research output: Contribution to journalReview article

56 Scopus citations
1997

Protein tyrosine kinases and cancer

Kolibaba, K. S. & Druker, B. J., Dec 9 1997, In : Biochimica et Biophysica Acta - Reviews on Cancer. 1333, 3, p. F217-F248

Research output: Contribution to journalReview article

265 Scopus citations
1989

Oncogenes, Growth Factors, and Signal Transduction

Flier, J. S., Underhill, L. H., Druker, B. J., Mamon, H. J. & Roberts, T. M., Nov 16 1989, In : New England Journal of Medicine. 321, 20, p. 1383-1391 9 p.

Research output: Contribution to journalReview article

241 Scopus citations
1983

BCG-induced macrophages as suppressor cells

Druker, B. J. & Wepsic, H. T., Jan 1 1983, In : Cancer Investigation. 1, 2, p. 151-161 11 p.

Research output: Contribution to journalReview article

7 Scopus citations